On Apr. 14, 2020, Sinovac Biotech announced that the Company had obtained approval to conduct a human clinical trial on an inactivated SARS-CoV-2 (commonly referred to as COVID-19) vaccine candidate. The vaccine development commenced at the end of January 2020.